Abstract 4915: Sensitivity to NAMPT inhibition: In vitro and in vivo characterization in ovarian cancer

作者
Jenny J. Hong,Martina S.J. McDermott,Neil A. O’Brien,Enrique Guandique,Tong Luo,Dennis J. Slamon
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:83 (7_Supplement): 4915-4915
标识
DOI:10.1158/1538-7445.am2023-4915
摘要

Abstract Previous in vitro work on determining the unique sensitivities of various cancers to nicotinamide phosphoribosyltransferase inhibitors (NAMPTis) has demonstrated promising effects of treating cancer cells with NAMPTis such as FK866 and KPT9274. These inhibitors act by disrupting cellular energy metabolism and reducing intracellular NAD+ levels. NAMPT inhibition thereby suppresses the proliferation of cancer cells which depend more heavily on the NAMPT enzyme to produce NAD+ than noncancerous cells. Using pan-cancer in vitro screens in a large panel of molecularly characterized cell lines (n = 496) we identified a subset of ovarian cancer, a cancer with a high unmet need due to lack of diverse targeted therapies, as being extremely sensitive to NAMPT inhibition. Subsequent in vivo work using CD-1 nude mice demonstrate that NAMPT inhibitors can successfully reduce the ovarian tumor burden and may be an effective treatment option of some ovarian cancers. Moreover, NAD+’s function as a substrate to the poly ADP-ribose polymerase (PARP) enzyme makes NAMPTis rational candidates for including in combination therapies with PARP inhibitors, several of which are approved for maintenance therapy for ovarian cancer. By using NAMPTis to disrupt the cellular metabolic process while simultaneously inhibiting PARP activity, an essential DNA damage repair enzyme, it is possible to exploit the dependence of ovarian cancer cells on functional PARP activity. This is particularly important in homologous recombination deficient subtypes. In addition to a synergistic growth inhibitory response in ovarian cancer cells, preclinical combination studies of NAMPTis with olaparib, an approved PARP inhibitor, exhibited higher levels of DNA damage accumulation than with single drug treatments. Our in vitro and in vivo characterizations of NAMPT inhibition suggest that NAMPTis as either single agents or in combination treatments with PARP inhibitors should be investigated further as potential treatment options for ovarian cancer patient populations. Citation Format: Jenny J. Hong, Martina S. McDermott, Neil A. O'Brien, Enrique Guandique, Tong Luo, Dennis J. Slamon. Sensitivity to NAMPT inhibition: In vitro and in vivo characterization in ovarian cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4915.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科目三的应助被小xy采纳,获得10
刚刚
Feng发布了新的文献求助10
1秒前
锦川完成签到,获得积分10
1秒前
1秒前
1秒前
2秒前
狗狗耳完成签到 ,获得积分10
2秒前
2秒前
3秒前
英吉利25发布了新的文献求助10
3秒前
dd完成签到,获得积分10
3秒前
搞怪的老九的应助被hhhhh采纳,获得10
3秒前
科研通AI6.4的应助被胡萝卜卜采纳,获得10
4秒前
4秒前
linlin发布了新的文献求助10
4秒前
5秒前
qcx完成签到,获得积分20
6秒前
6秒前
司艺发布了新的文献求助10
6秒前
Akim的应助被nunl采纳,获得10
7秒前
lyl发布了新的文献求助30
7秒前
稳妥发布了新的文献求助10
8秒前
8秒前
星辰大海的应助被ylf采纳,获得10
9秒前
秋风的应助被Feng采纳,获得20
10秒前
11秒前
11秒前
二分三分完成签到,获得积分0
13秒前
核桃的应助被cccc采纳,获得50
14秒前
元意完成签到 ,获得积分10
15秒前
CarryLJR发布了新的文献求助10
15秒前
lin的应助被胡萝卜卜采纳,获得10
16秒前
俏皮的玉米完成签到,获得积分10
16秒前
科学家发布了新的文献求助10
17秒前
shinez完成签到 ,获得积分10
18秒前
无所谓发布了新的文献求助10
18秒前
笨笨迎蓉完成签到,获得积分10
18秒前
超级故事关注了科研通微信公众号
18秒前
18秒前
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191314
求助须知:如何正确求助?哪些是违规求助? 9578210
关于积分的说明 21857267
捐赠科研通 7790624
什么是DOI,文献DOI怎么找? 3436606
关于科研通互助平台的介绍 2560359
邀请新用户注册赠送积分活动 2483305